{"id":15270,"date":"2012-08-28T23:30:00","date_gmt":"2012-08-28T21:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/astrazeneca-da-roche-arriva-il-nuovo-amministratore-delegato-soriot\/"},"modified":"2012-08-28T23:30:00","modified_gmt":"2012-08-28T21:30:00","slug":"astrazeneca-da-roche-arriva-il-nuovo-amministratore-delegato-soriot","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/astrazeneca-da-roche-arriva-il-nuovo-amministratore-delegato-soriot\/","title":{"rendered":"Astrazeneca: the new CEO Soriot arrives from Roche"},"content":{"rendered":"<p class=\"MsoNormal\" style=\"text-align: right; margin: 0cm 0cm 0pt\"><em><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\"><img decoding=\"async\" id=\"rg_hi\" class=\"rg_hi uh_hi\" alt=\"\" data-width=\"284\" data-height=\"177\" style=\"width: 284px; height: 177px\" src=\"https:\/\/encrypted-tbn2.google.com\/images?q=tbn:ANd9GcRVsrncBPz_iVfMPffsX4rxHJHZMUuoC8sqb3R4PGO-eiQ5u-Zlgg\" \/><\/span><\/em><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 0pt\"><em><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\">Finanzaonline.com \u2013 28.8.12\/09:10<\/span><\/em><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\"><\/p>\n<p> <\/span><span class=\"testo1\"><span style=\"mso-ansi-font-size: 12.0pt; mso-bidi-font-size: 12.0pt\"><font size=\"3\">Astrazeneca has appointed Pascal Soriot, former chief financial officer of Roche, as chief executive officer of the group. Soriot, 53, will take up his position at the British biopharmaceutical company from October 1, taking over from David Brennan in June. Interim Chief Executive Officer Simon Lowth will resume his post as Chief Financial Officer of Astrazeneca. <\/font><\/span><\/span><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black\"><br \/> <\/span><span style=\"font-family: &quot;Arial&quot;,&quot;sans-serif&quot;; color: black; font-size: 9pt\"><br \/> <span class=\"testo1\">Source: Finanza.com<\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 0pt\">&nbsp;<\/p>\n<p class=\"MsoNormal\" style=\"text-align: left; margin: 0cm 0cm 0pt\">&nbsp;<\/p>\n<div id=\"disqus_title\">\n<h1>AstraZeneca Names Roche&#039;s Pascal Soriot as CEO<\/h1>\n<\/p><\/div>\n<div id=\"story_meta\"><cite class=\"byline\">By Allison Connolly \u2013 <span class=\"datestamp\" bglocalize=\"true\" bgdatestamp=\"mmm d, yyyy h:MM TT Z\" epoch=\"1346136842000\" style=\"display: inline\">Aug 28, 2012 8:54 AM GMT+0200<\/span> <\/cite><\/div>\n<p><a class=\"web_ticker\" title=\"Get Quotes\" topic_url=\"http:\/\/topics.bloomberg.com\/astrazeneca-plc\/\" density=\"full\" ticker=\"AZN:LN\" href=\"http:\/\/www.bloomberg.com\/quote\/AZN:LN\" target=\"_blank\" rel=\"noopener\">AstraZeneca Plc (AZN)<\/a> named Pascal Soriot, <a class=\"web_ticker\" title=\"Get Quotes\" topic_url=\"http:\/\/topics.bloomberg.com\/roche-holding-ag\/\" density=\"full\" ticker=\"ROG:VX\" href=\"http:\/\/www.bloomberg.com\/quote\/ROG:VX\" target=\"_blank\" rel=\"noopener\">Roche Holding AG&#039;s (ROG)<\/a> head of pharmaceuticals, as chief executive officer to revive sales and product development as the UK company faces one of the industry&#039;s biggest patent expirations.&nbsp;<\/p>\n<div class=\"story_inline assets clearfix\">\n<div class=\"story_inline attachments\">\n<div class=\"image thumbnail item_container  first decoratable\" data-decoration-id=\"222857\" data-type=\"ImageAttachment\">\n<div class=\"thumbnail_container overlay_container\">\n<div id=\"img_222857\" class=\"simple_overlay\">\n<h3 class=\"image_title\" style=\"width: 640px\">AstraZeneca Names Roche&#039;s Soriot as CEO as Patent Expiries Loom<\/h3>\n<p> <img decoding=\"async\" class=\"img_keep_size\" alt=\"AstraZeneca Names Roche&rsquo;s Soriot as CEO as Patent Expiries Loom \" style=\"width: 485px; height: 291px\" src=\"http:\/\/www.bloomberg.com\/image\/i5.T1ehiU1GA.jpg\" \/> <\/p>\n<div class=\"details\" style=\"width: 640px\">\n<div class=\"subdetails\">\n<p class=\"photographer_attr\">Tim Shaffer\/Bloomber<\/p>\n<\/p><\/div>\n<p class=\"caption_only\">Soriot joins the London-based drugmaker as it searches for licensing deals, partnerships and acquisitions of late-stage assets to replenish the pipeline and boost sales.<\/p>\n<\/p><\/div><\/div><\/div>\n<p class=\"caption\" style=\"text-align: left\">Soriot joins the London-based drugmaker as it searches for licensing deals, partnerships and acquisitions of late-stage assets to replenish the pipeline and boost sales. Photographer: Tim Shaffer\/Bloomberg<\/p>\n<\/p><\/div><\/div><\/div>\n<p style=\"text-align: left\">Soriot, 53, will join AstraZeneca on Oct. 1, th<\/p>","protected":false},"excerpt":{"rendered":"<p>Finanzaonline.com &#8211; 28.8.12\/09:10 Astrazeneca ha nominato Pascal Soriot, ex direttore finanziario di Roche, come amministratore delegato del gruppo. Soriot, 53 anni, assumer&agrave; la carica nella societ&agrave; biofarmaceutica inglese a partire dal primo di ottobre, prendendo il posto lasciato a giugno da David Brennan. L&#8217;amministratore delegato ad interim, Simon Lowth, riprender&agrave; il suo incarico di direttore &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15270"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15270\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}